Malignant chondroid syringoma

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics

Malignant chondroid syringoma
Synonyms	Malignant mixed tumor of the skin
Pronounce	N/A
Specialty	N/A
Symptoms	Painless, slow-growing mass, often on the head or neck
Complications	Local recurrence, metastasis
Onset	Typically in adults
Duration	Chronic
Types	N/A
Causes	Unknown
Risks	Previous benign chondroid syringoma, age
Diagnosis	Biopsy, Histopathology
Differential diagnosis	Benign chondroid syringoma, Basal cell carcinoma, Squamous cell carcinoma
Prevention	N/A
Treatment	Surgical excision, Radiation therapy
Medication	None specific
Prognosis	Variable, depends on stage and treatment
Frequency	Rare
Deaths	N/A

34-year-old woman with malignant chondroid syringoma

Malignant chondroid syringoma (MCS), also known as malignant mixed tumor of the skin, is a rare type of cancer that primarily affects the skin. It is a malignant variant of chondroid syringoma, which is a benign tumor that originates from the sweat glands.

Epidemiology

Malignant chondroid syringoma is extremely rare, with fewer than 50 cases reported in the literature. It can occur at any age, but is most commonly diagnosed in adults between the ages of 30 and 60. There is no known gender or racial predilection.

Pathogenesis

The exact cause of malignant chondroid syringoma is unknown. It is believed to arise from the eccrine sweat glands, which are a type of sweat gland found throughout the body. The tumor is composed of both epithelial and mesenchymal components, reflecting its mixed origin.

Clinical Features

Patients with malignant chondroid syringoma typically present with a slow-growing, painless nodule on the skin. The most common locations are the head and neck, but the tumor can occur anywhere on the body. Other symptoms may include ulceration of the skin and regional lymphadenopathy.

Diagnosis

The diagnosis of malignant chondroid syringoma is made based on the clinical presentation and histopathological examination of the tumor. Immunohistochemistry may be used to confirm the diagnosis. The tumor cells typically express markers of both epithelial and mesenchymal differentiation.

Treatment

The mainstay of treatment for malignant chondroid syringoma is surgical excision of the tumor. Radiation therapy and chemotherapy may be used in cases where the tumor is not completely resectable or has metastasized to other parts of the body.

Prognosis

The prognosis of malignant chondroid syringoma is generally poor due to its aggressive nature and tendency to recur and metastasize. The 5-year survival rate is estimated to be less than 50%.

See Also

• Chondroid syringoma
• Eccrine sweat glands
• Cancer
• Immunohistochemistry

   This article is a skin-disease stub. You can help WikiMD by expanding it!

   This article is a oncology stub. You can help WikiMD by expanding it!